Citalopram Treatment of Pediatric Recurrent Abdominal Pain and Comorbid Internalizing Disorders: An Exploratory Study
To assess the potential efficacy, tolerability, and safety of citalopram in the treatment of functional pediatric recurrent abdominal pain and comorbid internalizing disorders. Twenty-five clinically referred children and adolescents with recurrent abdominal pain aged 7 to 18 years, inclusive, parti...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Child and Adolescent Psychiatry 2004-10, Vol.43 (10), p.1234-1242 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1242 |
|---|---|
| container_issue | 10 |
| container_start_page | 1234 |
| container_title | Journal of the American Academy of Child and Adolescent Psychiatry |
| container_volume | 43 |
| creator | CAMPO, JOHN V. PEREL, JAMES LUCAS, AMANDA BRIDGE, JEFF EHMANN, MARY KALAS, CATHERINE MONK, KELLY AXELSON, DAVID BIRMAHER, BORIS RYAN, NEAL Di LORENZO, CARLO BRENT, DAVID A. |
| description | To assess the potential efficacy, tolerability, and safety of citalopram in the treatment of functional pediatric recurrent abdominal pain and comorbid internalizing disorders.
Twenty-five clinically referred children and adolescents with recurrent abdominal pain aged 7 to 18 years, inclusive, participated in a 12-week, flexible-dose, open-label trial of citalopram. Primary outcome measure was the Clinical Global Impression Scale-Improvement, with responders defined by ratings of 1 (very much improved) or 2 (much improved). Secondary measures included self- and parent reports of abdominal pain, anxiety, depression, other somatic symptoms, and functional impairment. Side effects were assessed using a standardized checklist. Data were analyzed using an intent-to-treat format and the last observation carried forward procedure.
Twenty-one subjects (84%) were classified as responders (Clinical Global Impression Scale-Improvement score ≤2). Citalopram was generally well tolerated. Four subjects withdrew prematurely, one due to reported visual side effects. Ratings of abdominal pain, anxiety, depression, other somatic symptoms, and functional impairment all improved significantly over the course of the study compared with baseline.
Citalopram is a promising treatment for functional pediatric recurrent abdominal pain and deserves additional study with a randomized, placebo-controlled clinical trial. |
| doi_str_mv | 10.1097/01.chi.0000136563.31709.b0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_212633591</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ericid>EJ696589</ericid><els_id>S089085670961577X</els_id><sourcerecordid>711156341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c454t-fd3db94721851d1c52a1cd08c85209f9a56440975d93e12856d9ca52d3fceb103</originalsourceid><addsrcrecordid>eNqNkdFuFCEUhonR2LX6BsaQJr2ckTMMM9C7zXarNU1stF4TBhil2RlWYIzbp5dxJ-6t3JDwf3DO-UDoAkgJRLTvCZT6hytJXkAb1tCSQktE2ZFnaAWsagtWA3-OVoQLUnDWtGfoVYyPM99y_hKdAaMccrhC08YltfP7oAb8EKxKgx0T9j2-t8apFJzGX6yeQpiP153xgxvVDt8rN2I1Grzxgw-dM_h2TDbkyD258Tu-dtEHY0O8wusRb3_vdz6o5MMBf02TObxGL3q1i_bNsp-jbzfbh83H4u7zh9vN-q7QNatT0RtqOlG3FXAGBjSrFGhDuOasIqIXijV1nY0wI6iFKk9qhFasMrTXtgNCz9HF8d198D8nG5N89NPcZZQVVA2lTECGro6QDj7GYHu5D25Q4SCByFm4JCCzcHkSLv8Kl91c4d1SYeoGa05XF8MZuFwAFbXa9UGN2sUT1wAFxurMvT1yNjv_F28_NaJhXOT4eomzrl_OBhm1s6POvxSsTtJ49z_t_gGhvKnr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212633591</pqid></control><display><type>article</type><title>Citalopram Treatment of Pediatric Recurrent Abdominal Pain and Comorbid Internalizing Disorders: An Exploratory Study</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Journals@Ovid Complete</source><creator>CAMPO, JOHN V. ; PEREL, JAMES ; LUCAS, AMANDA ; BRIDGE, JEFF ; EHMANN, MARY ; KALAS, CATHERINE ; MONK, KELLY ; AXELSON, DAVID ; BIRMAHER, BORIS ; RYAN, NEAL ; Di LORENZO, CARLO ; BRENT, DAVID A.</creator><creatorcontrib>CAMPO, JOHN V. ; PEREL, JAMES ; LUCAS, AMANDA ; BRIDGE, JEFF ; EHMANN, MARY ; KALAS, CATHERINE ; MONK, KELLY ; AXELSON, DAVID ; BIRMAHER, BORIS ; RYAN, NEAL ; Di LORENZO, CARLO ; BRENT, DAVID A.</creatorcontrib><description>To assess the potential efficacy, tolerability, and safety of citalopram in the treatment of functional pediatric recurrent abdominal pain and comorbid internalizing disorders.
Twenty-five clinically referred children and adolescents with recurrent abdominal pain aged 7 to 18 years, inclusive, participated in a 12-week, flexible-dose, open-label trial of citalopram. Primary outcome measure was the Clinical Global Impression Scale-Improvement, with responders defined by ratings of 1 (very much improved) or 2 (much improved). Secondary measures included self- and parent reports of abdominal pain, anxiety, depression, other somatic symptoms, and functional impairment. Side effects were assessed using a standardized checklist. Data were analyzed using an intent-to-treat format and the last observation carried forward procedure.
Twenty-one subjects (84%) were classified as responders (Clinical Global Impression Scale-Improvement score ≤2). Citalopram was generally well tolerated. Four subjects withdrew prematurely, one due to reported visual side effects. Ratings of abdominal pain, anxiety, depression, other somatic symptoms, and functional impairment all improved significantly over the course of the study compared with baseline.
Citalopram is a promising treatment for functional pediatric recurrent abdominal pain and deserves additional study with a randomized, placebo-controlled clinical trial.</description><identifier>ISSN: 0890-8567</identifier><identifier>EISSN: 1527-5418</identifier><identifier>DOI: 10.1097/01.chi.0000136563.31709.b0</identifier><identifier>PMID: 15381890</identifier><identifier>CODEN: JAAPEE</identifier><language>eng</language><publisher>Hagerstown, MD: Elsevier Inc</publisher><subject>abdominal pain ; Abdominal Pain - drug therapy ; Abdominal Pain - psychology ; Adolescent ; Adolescents ; Anxiety ; Anxiety Disorders - complications ; Anxiety Disorders - drug therapy ; Biological and medical sciences ; Child ; Children ; Children & youth ; Chronic Illness ; Citalopram - administration & dosage ; Citalopram - adverse effects ; Citalopram - therapeutic use ; Comorbidity ; depression ; Depression (Psychology) ; Depression - complications ; Depression - drug therapy ; Drug Therapy ; Female ; Humans ; Male ; Medical sciences ; Mental disorders ; Neuropharmacology ; Outcome Measures ; Pain ; Pain management ; Parent Reports ; Pediatrics ; Pharmacology. Drug treatments ; Psychiatry ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psycholeptics: tranquillizer, neuroleptic ; Psychological Patterns ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Recurrence ; serotonin ; Serotonin Uptake Inhibitors - administration & dosage ; Serotonin Uptake Inhibitors - adverse effects ; Serotonin Uptake Inhibitors - therapeutic use ; Side effects ; Somatoform Disorders</subject><ispartof>Journal of the American Academy of Child and Adolescent Psychiatry, 2004-10, Vol.43 (10), p.1234-1242</ispartof><rights>2004 The American Academy of Child and Adolescent Psychiatry</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Lippincott Williams & Wilkins Oct 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c454t-fd3db94721851d1c52a1cd08c85209f9a56440975d93e12856d9ca52d3fceb103</citedby><cites>FETCH-LOGICAL-c454t-fd3db94721851d1c52a1cd08c85209f9a56440975d93e12856d9ca52d3fceb103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S089085670961577X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,30976,65306</link.rule.ids><backlink>$$Uhttp://eric.ed.gov/ERICWebPortal/detail?accno=EJ696589$$DView record in ERIC$$Hfree_for_read</backlink><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16131554$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15381890$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CAMPO, JOHN V.</creatorcontrib><creatorcontrib>PEREL, JAMES</creatorcontrib><creatorcontrib>LUCAS, AMANDA</creatorcontrib><creatorcontrib>BRIDGE, JEFF</creatorcontrib><creatorcontrib>EHMANN, MARY</creatorcontrib><creatorcontrib>KALAS, CATHERINE</creatorcontrib><creatorcontrib>MONK, KELLY</creatorcontrib><creatorcontrib>AXELSON, DAVID</creatorcontrib><creatorcontrib>BIRMAHER, BORIS</creatorcontrib><creatorcontrib>RYAN, NEAL</creatorcontrib><creatorcontrib>Di LORENZO, CARLO</creatorcontrib><creatorcontrib>BRENT, DAVID A.</creatorcontrib><title>Citalopram Treatment of Pediatric Recurrent Abdominal Pain and Comorbid Internalizing Disorders: An Exploratory Study</title><title>Journal of the American Academy of Child and Adolescent Psychiatry</title><addtitle>J Am Acad Child Adolesc Psychiatry</addtitle><description>To assess the potential efficacy, tolerability, and safety of citalopram in the treatment of functional pediatric recurrent abdominal pain and comorbid internalizing disorders.
Twenty-five clinically referred children and adolescents with recurrent abdominal pain aged 7 to 18 years, inclusive, participated in a 12-week, flexible-dose, open-label trial of citalopram. Primary outcome measure was the Clinical Global Impression Scale-Improvement, with responders defined by ratings of 1 (very much improved) or 2 (much improved). Secondary measures included self- and parent reports of abdominal pain, anxiety, depression, other somatic symptoms, and functional impairment. Side effects were assessed using a standardized checklist. Data were analyzed using an intent-to-treat format and the last observation carried forward procedure.
Twenty-one subjects (84%) were classified as responders (Clinical Global Impression Scale-Improvement score ≤2). Citalopram was generally well tolerated. Four subjects withdrew prematurely, one due to reported visual side effects. Ratings of abdominal pain, anxiety, depression, other somatic symptoms, and functional impairment all improved significantly over the course of the study compared with baseline.
Citalopram is a promising treatment for functional pediatric recurrent abdominal pain and deserves additional study with a randomized, placebo-controlled clinical trial.</description><subject>abdominal pain</subject><subject>Abdominal Pain - drug therapy</subject><subject>Abdominal Pain - psychology</subject><subject>Adolescent</subject><subject>Adolescents</subject><subject>Anxiety</subject><subject>Anxiety Disorders - complications</subject><subject>Anxiety Disorders - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Children</subject><subject>Children & youth</subject><subject>Chronic Illness</subject><subject>Citalopram - administration & dosage</subject><subject>Citalopram - adverse effects</subject><subject>Citalopram - therapeutic use</subject><subject>Comorbidity</subject><subject>depression</subject><subject>Depression (Psychology)</subject><subject>Depression - complications</subject><subject>Depression - drug therapy</subject><subject>Drug Therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental disorders</subject><subject>Neuropharmacology</subject><subject>Outcome Measures</subject><subject>Pain</subject><subject>Pain management</subject><subject>Parent Reports</subject><subject>Pediatrics</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatry</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychological Patterns</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Recurrence</subject><subject>serotonin</subject><subject>Serotonin Uptake Inhibitors - administration & dosage</subject><subject>Serotonin Uptake Inhibitors - adverse effects</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>Side effects</subject><subject>Somatoform Disorders</subject><issn>0890-8567</issn><issn>1527-5418</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqNkdFuFCEUhonR2LX6BsaQJr2ckTMMM9C7zXarNU1stF4TBhil2RlWYIzbp5dxJ-6t3JDwf3DO-UDoAkgJRLTvCZT6hytJXkAb1tCSQktE2ZFnaAWsagtWA3-OVoQLUnDWtGfoVYyPM99y_hKdAaMccrhC08YltfP7oAb8EKxKgx0T9j2-t8apFJzGX6yeQpiP153xgxvVDt8rN2I1Grzxgw-dM_h2TDbkyD258Tu-dtEHY0O8wusRb3_vdz6o5MMBf02TObxGL3q1i_bNsp-jbzfbh83H4u7zh9vN-q7QNatT0RtqOlG3FXAGBjSrFGhDuOasIqIXijV1nY0wI6iFKk9qhFasMrTXtgNCz9HF8d198D8nG5N89NPcZZQVVA2lTECGro6QDj7GYHu5D25Q4SCByFm4JCCzcHkSLv8Kl91c4d1SYeoGa05XF8MZuFwAFbXa9UGN2sUT1wAFxurMvT1yNjv_F28_NaJhXOT4eomzrl_OBhm1s6POvxSsTtJ49z_t_gGhvKnr</recordid><startdate>20041001</startdate><enddate>20041001</enddate><creator>CAMPO, JOHN V.</creator><creator>PEREL, JAMES</creator><creator>LUCAS, AMANDA</creator><creator>BRIDGE, JEFF</creator><creator>EHMANN, MARY</creator><creator>KALAS, CATHERINE</creator><creator>MONK, KELLY</creator><creator>AXELSON, DAVID</creator><creator>BIRMAHER, BORIS</creator><creator>RYAN, NEAL</creator><creator>Di LORENZO, CARLO</creator><creator>BRENT, DAVID A.</creator><general>Elsevier Inc</general><general>Lippincott Williams & Wilkins</general><general>Lippincott</general><general>Elsevier BV</general><scope>7SW</scope><scope>BJH</scope><scope>BNH</scope><scope>BNI</scope><scope>BNJ</scope><scope>BNO</scope><scope>ERI</scope><scope>PET</scope><scope>REK</scope><scope>WWN</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7TK</scope><scope>K9.</scope></search><sort><creationdate>20041001</creationdate><title>Citalopram Treatment of Pediatric Recurrent Abdominal Pain and Comorbid Internalizing Disorders: An Exploratory Study</title><author>CAMPO, JOHN V. ; PEREL, JAMES ; LUCAS, AMANDA ; BRIDGE, JEFF ; EHMANN, MARY ; KALAS, CATHERINE ; MONK, KELLY ; AXELSON, DAVID ; BIRMAHER, BORIS ; RYAN, NEAL ; Di LORENZO, CARLO ; BRENT, DAVID A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c454t-fd3db94721851d1c52a1cd08c85209f9a56440975d93e12856d9ca52d3fceb103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>abdominal pain</topic><topic>Abdominal Pain - drug therapy</topic><topic>Abdominal Pain - psychology</topic><topic>Adolescent</topic><topic>Adolescents</topic><topic>Anxiety</topic><topic>Anxiety Disorders - complications</topic><topic>Anxiety Disorders - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Children</topic><topic>Children & youth</topic><topic>Chronic Illness</topic><topic>Citalopram - administration & dosage</topic><topic>Citalopram - adverse effects</topic><topic>Citalopram - therapeutic use</topic><topic>Comorbidity</topic><topic>depression</topic><topic>Depression (Psychology)</topic><topic>Depression - complications</topic><topic>Depression - drug therapy</topic><topic>Drug Therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental disorders</topic><topic>Neuropharmacology</topic><topic>Outcome Measures</topic><topic>Pain</topic><topic>Pain management</topic><topic>Parent Reports</topic><topic>Pediatrics</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatry</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychological Patterns</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Recurrence</topic><topic>serotonin</topic><topic>Serotonin Uptake Inhibitors - administration & dosage</topic><topic>Serotonin Uptake Inhibitors - adverse effects</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>Side effects</topic><topic>Somatoform Disorders</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CAMPO, JOHN V.</creatorcontrib><creatorcontrib>PEREL, JAMES</creatorcontrib><creatorcontrib>LUCAS, AMANDA</creatorcontrib><creatorcontrib>BRIDGE, JEFF</creatorcontrib><creatorcontrib>EHMANN, MARY</creatorcontrib><creatorcontrib>KALAS, CATHERINE</creatorcontrib><creatorcontrib>MONK, KELLY</creatorcontrib><creatorcontrib>AXELSON, DAVID</creatorcontrib><creatorcontrib>BIRMAHER, BORIS</creatorcontrib><creatorcontrib>RYAN, NEAL</creatorcontrib><creatorcontrib>Di LORENZO, CARLO</creatorcontrib><creatorcontrib>BRENT, DAVID A.</creatorcontrib><collection>ERIC</collection><collection>ERIC (Ovid)</collection><collection>ERIC</collection><collection>ERIC</collection><collection>ERIC (Legacy Platform)</collection><collection>ERIC( SilverPlatter )</collection><collection>ERIC</collection><collection>ERIC PlusText (Legacy Platform)</collection><collection>Education Resources Information Center (ERIC)</collection><collection>ERIC</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CAMPO, JOHN V.</au><au>PEREL, JAMES</au><au>LUCAS, AMANDA</au><au>BRIDGE, JEFF</au><au>EHMANN, MARY</au><au>KALAS, CATHERINE</au><au>MONK, KELLY</au><au>AXELSON, DAVID</au><au>BIRMAHER, BORIS</au><au>RYAN, NEAL</au><au>Di LORENZO, CARLO</au><au>BRENT, DAVID A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><ericid>EJ696589</ericid><atitle>Citalopram Treatment of Pediatric Recurrent Abdominal Pain and Comorbid Internalizing Disorders: An Exploratory Study</atitle><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle><addtitle>J Am Acad Child Adolesc Psychiatry</addtitle><date>2004-10-01</date><risdate>2004</risdate><volume>43</volume><issue>10</issue><spage>1234</spage><epage>1242</epage><pages>1234-1242</pages><issn>0890-8567</issn><eissn>1527-5418</eissn><coden>JAAPEE</coden><abstract>To assess the potential efficacy, tolerability, and safety of citalopram in the treatment of functional pediatric recurrent abdominal pain and comorbid internalizing disorders.
Twenty-five clinically referred children and adolescents with recurrent abdominal pain aged 7 to 18 years, inclusive, participated in a 12-week, flexible-dose, open-label trial of citalopram. Primary outcome measure was the Clinical Global Impression Scale-Improvement, with responders defined by ratings of 1 (very much improved) or 2 (much improved). Secondary measures included self- and parent reports of abdominal pain, anxiety, depression, other somatic symptoms, and functional impairment. Side effects were assessed using a standardized checklist. Data were analyzed using an intent-to-treat format and the last observation carried forward procedure.
Twenty-one subjects (84%) were classified as responders (Clinical Global Impression Scale-Improvement score ≤2). Citalopram was generally well tolerated. Four subjects withdrew prematurely, one due to reported visual side effects. Ratings of abdominal pain, anxiety, depression, other somatic symptoms, and functional impairment all improved significantly over the course of the study compared with baseline.
Citalopram is a promising treatment for functional pediatric recurrent abdominal pain and deserves additional study with a randomized, placebo-controlled clinical trial.</abstract><cop>Hagerstown, MD</cop><pub>Elsevier Inc</pub><pmid>15381890</pmid><doi>10.1097/01.chi.0000136563.31709.b0</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0890-8567 |
| ispartof | Journal of the American Academy of Child and Adolescent Psychiatry, 2004-10, Vol.43 (10), p.1234-1242 |
| issn | 0890-8567 1527-5418 |
| language | eng |
| recordid | cdi_proquest_journals_212633591 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Elsevier ScienceDirect Journals; Journals@Ovid Complete |
| subjects | abdominal pain Abdominal Pain - drug therapy Abdominal Pain - psychology Adolescent Adolescents Anxiety Anxiety Disorders - complications Anxiety Disorders - drug therapy Biological and medical sciences Child Children Children & youth Chronic Illness Citalopram - administration & dosage Citalopram - adverse effects Citalopram - therapeutic use Comorbidity depression Depression (Psychology) Depression - complications Depression - drug therapy Drug Therapy Female Humans Male Medical sciences Mental disorders Neuropharmacology Outcome Measures Pain Pain management Parent Reports Pediatrics Pharmacology. Drug treatments Psychiatry Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psycholeptics: tranquillizer, neuroleptic Psychological Patterns Psychology. Psychoanalysis. Psychiatry Psychopharmacology Recurrence serotonin Serotonin Uptake Inhibitors - administration & dosage Serotonin Uptake Inhibitors - adverse effects Serotonin Uptake Inhibitors - therapeutic use Side effects Somatoform Disorders |
| title | Citalopram Treatment of Pediatric Recurrent Abdominal Pain and Comorbid Internalizing Disorders: An Exploratory Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T19%3A16%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Citalopram%20Treatment%20of%20Pediatric%20Recurrent%20Abdominal%20Pain%20and%20Comorbid%20Internalizing%20Disorders:%20An%20Exploratory%20Study&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Child%20and%20Adolescent%20Psychiatry&rft.au=CAMPO,%20JOHN%20V.&rft.date=2004-10-01&rft.volume=43&rft.issue=10&rft.spage=1234&rft.epage=1242&rft.pages=1234-1242&rft.issn=0890-8567&rft.eissn=1527-5418&rft.coden=JAAPEE&rft_id=info:doi/10.1097/01.chi.0000136563.31709.b0&rft_dat=%3Cproquest_cross%3E711156341%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212633591&rft_id=info:pmid/15381890&rft_ericid=EJ696589&rft_els_id=S089085670961577X&rfr_iscdi=true |